Table 2.
Characteristics of included studies, including methodological quality assessment.
| Reference (Year) | Single or Multi Center Study | n Included for Review (Total) | Indication | Finding Group(s) | MINORS Score (0–14) |
|---|---|---|---|---|---|
| Adler DG (2004) [18] | Single | 20 (20) | GI bleeding | Blood; Erosions/Ulcerations | 11 |
| Alageeli M (2020) [19] | Multi | 25 (25) | GI bleeding, CD, screening for HPS | Cleanliness | 11 |
| Albert J (2004) [20] | Single | 36 (36) | OGIB, suspected CD, suspected SB tumor, refractory sprue, FAP | Cleanliness | 12 |
| Arieira C (2019) [21] | Single | 22 (22) | Known CD | IBD | 8 |
| Biagi F (2006) [22] | Multi | 21 (32) | CeD, IBS, known CD | Villous atrophy | 10 |
| Blanco-Velasco G (2021) [23] | Single | 100 (100) | IDA, GI bleeding, known CD, SB tumors, diarrhea | Blood; IBD; Blended outcomes | 11 |
| Bossa F (2006) [24] | Single | 39 (41) | OGIB, HPS, known CD, CeD, diarrhea | Blood; Blended outcomes; Other lesions; Polyps; Erosions/Ulcerations; Angiodysplasias | 8 |
| Bourreille A (2006) [25] | Multi | 32 (32) | IIleocolonic resection | Blended outcomes; Other lesions; Villous atrophy; Erosions/Ulcerations | 12 |
| Brotz C (2009) [26] | Single | 40 (541) | GI bleeding, abdominal pain, diarrhea, anemia, follow-up of prior findings | Cleanliness | 10 |
| Buijs MM (2018) [27] | Single | 42 (136) | CRC screening | Blended outcomes; Polyps; Cleanliness | 13 |
| Chavalitdhamrong D (2012) [28] | Multi | 65 (65) | Portal hypertension | Other lesions | 12 |
| Chetcuti Zammit S (2021) [29] | Multi | 300 (300) | CeD, seronegative villous atrophy | IBD; Villous atrophy; Erosions/Ulcerations; Blended outcomes | 13 |
| Christodoulou D (2007) [30] | Single | 20 (20) | GI bleeding | Other lesions; Angiodysplasias; Polyps; Blood | 11 |
| Cotter J (2015) [31] | Single | 70 (70) | Known CD | IBD | 12 |
| De Leusse A (2005) [32] | Single | 30 (64) | GI bleeding | Blood; Angiodysplasias; Other lesions; Erosions/Ulcerations; Blended outcomes; | 12 |
| de Sousa Magalhães R (2021) [33] | Single | 58 (58) | Incomplete colonoscopy | Cleanliness | 11 |
| Delvaux M (2008) [34] | Multi | 96 (98) | Known or suspected esophageal disease | Blended outcomes | 13 |
| D’Haens G (2015) [35] | Multi | 20 (40) | Known CD | IBD | 11 |
| Dray X (2021) [36] | Multi | 155 (637) | OGIB | Cleanliness | 12 |
| Duque G (2012) [37] | Single | 20 (20) | GI bleeding | Blended outcomes | 11 |
| Eliakim R (2020) [38] | Single | 54 (54) | Known CD | IBD | 11 |
| Esaki M (2009) [39] | Single | 75 (102) | OGIB, FAP, GI lymphoma, PJS, GIST, carcinoid tumor | Cleanliness | 12 |
| Esaki M (2019) [40] | Multi | 50 (108) | Suspected CD | Other lesions; Erosions/Ulcerations | 10 |
| Ewertsen C (2006) [41] | Single | 33 (34) | OGIB, carcinoid tumors, angiodysplasias, diarrhea, immune deficiency, diverticular disease | Blended outcomes | 8 |
| Gal E (2008) [42] | Single | 20 (20) | Known CD | IBD | 7 |
| Galmiche JP (2008) [43] | Multi | 77 (89) | GERD symptoms | Other lesions | 12 |
| Garcia-Compean D (2021) [44] | Single | 22 (22) | SB angiodysplasias | Angiodysplasias; Blended outcomes | 12 |
| Ge ZZ (2006) [45] | Single | 56 (56) | OGIB, suspected CD, abdominal pain, suspected SB tumor, FAP, diarrhea, sprue | Cleanliness | 12 |
| Girelli CM (2011) [46] | Single | 25 (35) | Suspected submucosal lesion | Other lesions | 12 |
| Goyal J (2014) [47] | Single | 34 (34) | NA | Cleanliness | 11 |
| Gupta A (2010) [48] | Single | 20 (20) | PJS | Polyps | 11 |
| Gupta T (2011) [49] | Single | 60 (60) | OGIB | Other lesions | 12 |
| Hong-Bin C (2013) [50] | Single | 63 (63) | GI bleeding, abdominal pain, chronic diarrhea | Cleanliness | 11 |
| Jang BI (2010) [51] | Multi | 56 (56) | NA | Blended outcomes | 10 |
| Jensen MD (2010) [52] | Single | 30 (30) | Known or suspected CD | Other lesions; IBD; Blended outcomes | 11 |
| Lai LH (2006) [53] | Single | 58 (58) | OGIB, known CD, abdominal pain | Blended outcomes | 10 |
| Lapalus MG (2009) [54] | Multi | 107 (120) | Portal hypertension | Other lesions | 11 |
| Laurain A (2014) [55] | Multi | 77 (80) | Portal hypertension | Other lesions | 12 |
| Laursen EL (2009) [56] | Single | 30 (30) | NA | Blended outcomes | 12 |
| Leighton JA (2011) [57] | Multi | 40 (40) | Healthy volunteers | Cleanliness | 13 |
| Murray JA (2008) [58] | Single | 37 (40) | CeD | IBD; Villous atrophy | 12 |
| Niv Y (2005) [59] | Single | 50 (50) | IDA, abdominal pain, known CD, CeD, GI lymphoma, SB transplant | Blended outcomes | 11 |
| Niv Y (2012) [60] | Multi | 50 (54) | Known CD | IBD | 13 |
| Oliva S (2014) [61] | Single | 29 (29) | UC | IBD | 14 |
| Oliva S (2014) [62] | Single | 198 (204) | Suspected IBD, OGIB, other symptoms | Cleanliness | 12 |
| Omori T (2020) [63] | Single | 20 (196) | Known CD | IBD | 8 |
| Park SC (2010) [64] | Single | 20 (20) | GI bleeding, IDA, abdominal pain, diarrhea | Cleanliness; Blended outcomes | 8 |
| Petroniene R (2005) [65] | Single | 20 (20) | CeD, villous atrophy | Villous atrophy | 12 |
| Pezzoli A (2011) [66] | Multi | 75 (75) | NA | Blood; Blended outcomes | 12 |
| Pons Beltrán V (2011) [67] | Multi | 31 (273) | GI bleeding, suspected CD | Cleanliness | 14 |
| Qureshi WA (2008) [68] | Single | 18 (20) | BE | Other lesions | 11 |
| Ravi S (2022) [69] | Single | 10 (22) | GI bleeding | Other lesions | 14 |
| Rimbaş M (2016) [70] | Single | 64 (64) | SB ulcerations | IBD | 12 |
| Rondonotti E (2014) [71] | Multi | 32 (32) | NA | Other lesions | 11 |
| Sciberras M (2022) [72] | Multi | 100 (182) | Suspected submucosal lesion | Other lesions | 10 |
| Shi HY (2017) [73] | Single | 30 (150) | UC | IBD; Blood; Erosions/Ulcerations | 14 |
| Triantafyllou K (2007) [74] | Multi | 87 (87) | Diabetes mellitus | Cleanliness; Blended outcomes | 11 |
| Usui S (2014) [75] | Single | 20 (20) | UC | IBD | 9 |
| Wong RF (2006) [76] | Single | 19 (32) | FAP | Polyps | 13 |
| Zakaria MS (2009) [77] | Single | 57 (57) | OGIB | Blended outcomes | 9 |
Abbreviations: BE, Barrett’s esophagus; CD, Crohn’s disease; CeD, celiac disease; CRC, colorectal cancer; FAP, familial adenomatous polyposis; GERD, gastroesophageal reflux disease; GI, gastrointestinal; GIST, gastrointestinal stromal tumor; HPS; hereditary polyposis syndrome; IBS, irritable bowel syndrome; IDA, iron-deficiency anemia; NA, not available; OGIB, obscure gastrointestinal bleeding; PJS, Peutz–Jeghers syndrome; SB, small bowel; UC, ulcerative colitis.